Atai Life Sciences N.V.

ATAI

NL0015000DX5

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.93 ^USD	+4.89%		+4.32%	+36.88%

Apr. 24	Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	CI
Apr. 17	Clarify Pharma to change name to File Forge Technology	AN

Beckley Psytech Limited announced that it has received $40 million in funding from Atai Life Sciences N.V.

January 03, 2024

Beckley Psytech Limited announced that it has received $40 million in a round of funding on January 4, 2024. The transaction included participation from new investor Atai Life Sciences N.V.

Latest news about Atai Life Sciences N.V.

Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech?s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	Apr. 24	CI
Clarify Pharma to change name to File Forge Technology	Apr. 17	AN
Atai Life Sciences Announces the Publication of Beckley Psytech?s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	Apr. 17	CI
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 03	MT
Atai Life Sciences Shares Rise Following Maxim Upgrade	Apr. 03	MT
Maxim Upgrades Atai Life Sciences to Buy From Hold, Price Target is $6	Apr. 03	MT
HC Wainwright Cuts Atai Life Sciences Price Target to $15 From $20, Maintains Buy Rating	Apr. 03	MT
Atai Life Sciences N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Atai Life Sciences N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech?s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	Mar. 27	CI
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences	Mar. 11	MT
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences	Mar. 11	MT
Atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01	Mar. 04	CI
Atai Life Sciences Announces Management Changes	Feb. 06	CI
Atai Life Sciences Acquires Stake in Beckley Psytech	Jan. 04	MT
Transcript : Atai Life Sciences N.V. - Special Call	Jan. 04
Beckley Psytech Limited announced that it has received $40 million in funding from Atai Life Sciences N.V.	Jan. 03	CI
Atai Rallies after Positive Data for Potential PTSD Treatment	Jan. 02	MT
Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)	Jan. 02	CI
IntelGenx Announcing Shareholder Approval of Financing Transactions	Nov. 28	MT
Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Atai Life Sciences N.V. acquired remaining stake of DemeRx IB, Inc. for $16 million.	Nov. 13	CI
Atai Life Sciences Reports 'Supportive' Results From Phase 1 Study of Oral Transmucosal Film	23-10-02	MT
Atai Life Sciences N.V. Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants	23-10-02	CI
IntelGenx Closes First Tranche of Private Placement From Strategic Partner For Aggregate Proceeds of US$3 Million	23-08-31	MT

ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Atai Life Sciences N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.93 USD

Average target price

11.8 USD

Spread / Average Target

+511.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ATAI LIFE SCIENCES N.V.	+36.88%	323M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Atai Life Sciences N.V.

Equities

ATAI

NL0015000DX5

Biotechnology & Medical Research

Beckley Psytech Limited announced that it has received $40 million in funding from Atai Life Sciences N.V.

Latest news about Atai Life Sciences N.V.

Chart Atai Life Sciences N.V.

Company Profile

Income Statement Evolution

Ratings for Atai Life Sciences N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research